Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus

M D Köller, E Templ, M Riedl, M Clodi, O Wagner, J S Smolen, A Luger


PATIENTS AND METHODS

Patients and healthy controls

The protocol was approved by the local ethics committee. Written consent was obtained from all participants. Eleven patients with SLE according to the revised, updated criteria of the American College of Rheumatology were included: eight women (two of them postmenopausal) and three men with a mean (SEM) age of 34.1 (4.9) years. Disease activity was evaluated by European Consensus Lupus Activity Measurement (ECLAM) score and SLE Disease Activity Index (SLEDAI). None of the patients had ever been treated with corticosteroids or immunosuppressive agents. Ten patients had mild to moderate disease, one patient had high activity with lupus nephritis: mean (SEM) ECLAM score 3.8 (0.6), mean (SEM) SLEDAI 9.3 (1.8). Table 1 gives the demographic data.

Seven women (two of them postmenopausal) and two men with a mean (SEM) age of 38.3 (4.1) years served as healthy controls (HC).

Stimulation test and hormone assay

We performed a combined test for total anterior pituitary gland reserve with all hypothalamic releasing hormones. All participants had refrained from food and drink for at least 4 hours before testing. Baseline blood samples were taken after a 30 minute rest at 04 00 pm. Then releasing hormones were injected simultaneously as a bolus: 100 μg corticotropin-releasing hormone (CRH; Ferring, Cologne, FRG), 100 μg growth hormone-releasing hormone (GHRH; Ferring, Cologne, Germany), 200 μg thyrotropin-releasing hormone (TRH; Behring, Vienna, Austria), and 100 μg GnRH (Aventis, Frankfurt, Germany). Peripheral blood levels of adrenocorticotropic hormone (ACTH), cortisol, GH, thyroid stimulating hormone (TSH), PRL, as well as luteinising hormone (LH) and follicle stimulating hormone (FSH) were measured at baseline and after injection. Baseline values of oestradiol, testosterone, and thyroxine were determined.

Conclusion: No significant alteration of the HPA axis was found in patients with SLE, which is inadequate, in view of the continuing inflammation. GH and PRL secretion were normal. The pituitary-thyroid and pituitary-gonadal axes were affected in patients with newly diagnosed, untreated SLE.

Abbreviations:

ACTH, adrenocorticotropic; CRH, corticotropin-releasing hormone; CV, coefficient of variation; DHEA, dehydroepiandrosterone; ECLAM, European Consensus Lupus Activity Measurement; FSH, follicle stimulating hormone; GH, growth hormone; GHRH, growth hormone-releasing hormone; GnRH, gonadotropin-releasing hormone; HC, healthy controls; HPA, hypothalamic-pituitary-adrenal; IL, interleukin; LH, luteinising hormone; PRL, prolactin; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index; T4, thyroxine; TNF, tumour necrosis factor; TRH, thyrotropin-releasing hormone; TSH, thyroid stimulating hormone

S

Studies show that the neuroendocrine system influences immunity and vice versa. Inflammation is accompanied by raised levels of cytokines like interleukin (IL)6 or tumour necrosis factor (TNFα) that can activate the hypothalamic-pituitary-adrenal (HPA) axis.

Evidence exists showing a link between sex hormones and the development of autoimmune diseases. The prevalence of systemic lupus erythematosus (SLE) is greatest in young women. This is one of the most obvious clinical observations in both, humans and animals, suggesting a causal role for sex steroids in the pathogenesis of SLE. Prolactin (PRL) influences lymphocyte function by inducing IL2 receptor expression. Furthermore, exogenous gonadotropin-releasing hormone (GnRH) increases disease activity in lupus prone mice.

Most studies elucidating the interaction of the endocrine network and autoimmunity in SLE have been performed in patients with longlasting disease and who therefore have a history of glucocorticoid intake. This may limit the interpretation of those results. Therefore, we investigated the total anterior pituitary reserve in patients with SLE before the initiation of glucocorticoid or immunosuppressive treatment.
enzyme immunological tests (all from Boehringer Mannheim GmbH, Mannheim, FRG), and LH by time resolved fluoroimmunoassay (CV < 5%; Wallac, Turku, Finland).

Statistical analysis
Data in the figures are expressed as mean (SEM). Statistical distribution was analysed by Kolmogorov-Smirnov test and values were compared using an unpaired t test. A p value < 0.05 was considered significant. All statistics were calculated with GraphPad Prism 3.0.

RESULTS
After injection of CRH a significant increase of ACTH was detected, which tended to be higher in patients with SLE (peak levels after 30 minutes: SLE 65.9 (25.9) pg/ml v HC 46.3 (9.9) pg/ml). However, differences were not statistically significant. Though basal cortisol levels tended to be higher in patients than in HC (290 (40) nmol/l v 220 (30) nmol/l), cortisol release was comparable with maximum concentrations 60 minutes after stimulation (SLE 500 (40) nmol/l v HC 510 (30) nmol/l).

Basal T4 levels (88.1 (3.5) ng/ml in patients with SLE v 78.0 (4.2) ng/ml in controls, NS) were comparable. After TRH injection significantly higher TSH levels were measured in patients than in controls (p < 0.05; fig 1). In contrast, basal (SLE 11.1 (1.2) ng/ml v HC 9.8 (1.8) ng/ml) and TRH stimulated PRL concentrations (maximum after 15 minutes; SLE 100.5 (14.8) ng/ml v HC 110.4 (19.5) ng/ml) were similar.

At baseline and after GHRH injection, GH levels were almost identical in both groups (basal: SLE 2.1 (0.6) ng/ml v HC 2.1 (0.9) ng/ml; 30 minute peak: SLE 20.5 (4.2) ng/ml v HC 24.0 (6.3) ng/ml).

After GnRH injection LH and FSH levels were virtually identical in premenopausal female patients compared with controls. Interestingly, two of the three male patients were clearly hypogonadal with low testosterone serum concentrations (table 1) but (inadequately) normal basal gonadotropin

Table 1: Patient characteristics

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age</th>
<th>ECLAM</th>
<th>SLEDAI</th>
<th>ANA</th>
<th>dsDNA Ab</th>
<th>C3</th>
<th>C4</th>
<th>CH50</th>
<th>ESR</th>
<th>CRP</th>
<th>T4</th>
<th>Oe2</th>
<th>Testosterone</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>25</td>
<td>2</td>
<td>6</td>
<td>1/5120</td>
<td>18.6</td>
<td>54.7</td>
<td>18.6</td>
<td>81.2</td>
<td>67</td>
<td>5</td>
<td>82.0</td>
<td>10.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>20</td>
<td>2</td>
<td>6</td>
<td>1/1280</td>
<td>58.0</td>
<td>56.6</td>
<td>5.8</td>
<td>76.1</td>
<td>24</td>
<td>5</td>
<td>84.0</td>
<td>21.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>23</td>
<td>3</td>
<td>5</td>
<td>1/160</td>
<td>84.4</td>
<td>37.7</td>
<td>15.3</td>
<td>37.8</td>
<td>36</td>
<td>5</td>
<td>72.0</td>
<td>10.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>26</td>
<td>5</td>
<td>12</td>
<td>1/5120</td>
<td>6.2</td>
<td>70.8</td>
<td>29.8</td>
<td>87.9</td>
<td>25</td>
<td>4</td>
<td>80.0</td>
<td>31.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>26</td>
<td>5</td>
<td>11</td>
<td>1/5120</td>
<td>155.0</td>
<td>40.0</td>
<td>6.6</td>
<td>55.6</td>
<td>70</td>
<td>16</td>
<td>81.0</td>
<td>41.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>49</td>
<td>5</td>
<td>12</td>
<td>1/2560</td>
<td>43.0</td>
<td>53.5</td>
<td>9.0</td>
<td>100.2</td>
<td>85</td>
<td>5</td>
<td>89.0</td>
<td>20.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>23</td>
<td>2</td>
<td>6</td>
<td>1/640</td>
<td>59.0</td>
<td>108.0</td>
<td>18.7</td>
<td>155.0</td>
<td>45</td>
<td>16</td>
<td>104.0</td>
<td>10.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>50</td>
<td>4</td>
<td>8</td>
<td>1/160</td>
<td>73.1</td>
<td>39.0</td>
<td>8.2</td>
<td>115.1</td>
<td>68</td>
<td>14</td>
<td>107.0</td>
<td>12.0</td>
<td>ND</td>
</tr>
<tr>
<td>M</td>
<td>34</td>
<td>2</td>
<td>7</td>
<td>1/80</td>
<td>84.7</td>
<td>148.0</td>
<td>42.2</td>
<td>144.0</td>
<td>21</td>
<td>63</td>
<td>90.0</td>
<td>3.89</td>
<td>ND</td>
</tr>
<tr>
<td>M</td>
<td>27</td>
<td>9</td>
<td>25</td>
<td>1/2560</td>
<td>737.0</td>
<td>13.5</td>
<td>6.6</td>
<td>31.8</td>
<td>93</td>
<td>9</td>
<td>78.0</td>
<td>21.0</td>
<td>ND</td>
</tr>
<tr>
<td>F</td>
<td>29</td>
<td>9</td>
<td>25</td>
<td>1/5120</td>
<td>101.0</td>
<td>80.2</td>
<td>15.2</td>
<td>93.7</td>
<td>70</td>
<td>78</td>
<td>102.0</td>
<td>1.98</td>
<td>ND</td>
</tr>
</tbody>
</table>

Sex (F, female; M, male), age (years); ECLAM, European Consensus of Lupus Activity Measurement; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ANA, antinuclear antibody titre (tested on Hep-2); dsDNA Ab, antibodies against dsDNA (measured by radioimmunoassay; U/ml; normal range < 7.0); C3, C4, complement factors (C3, normal range 50–90 mg/ml; C4, normal range 10–40 mg/ml); CH50, total haemolytic complement activity (normal range 50–150%); ESR, erythrocyte sedimentation rate (mm/1st h); CRP, C reactive protein (normal range < 5 mg/l); T4, thyroxin (normal range 50–120 ng/ml); Oe2, oestradiol (normal range 22–232 pg/ml; ND, not determined in men); testosterone (normal range 2.7–10.7 ng/ml; ND, not determined in women).

Figure 1: Thyroid stimulating hormone serum concentrations before and after pituitary stimulation by thyrotropin-releasing hormone (TRH) in patients with SLE and healthy controls.

Figure 2: Serum levels of (A) luteinising hormone (LH) and (B) follicle stimulating hormone (FSH) before and after pituitary stimulation by gonadotropin-releasing hormone (GnRH) in male patients with SLE and healthy controls.
concentrations. However, excessive stimulatory capacity in response to GnRH was retained and even tended to be higher (fig 2A). Owing to the limited number of men tested, the difference failed significance (fig 2B).

Within the SLE group we found no significant differences between female or male patients in their pituitary response after stimulation.

**DISCUSSION**

We analysed the overall pituitary end organ function in patients with newly diagnosed SLE who had not received glucocorticoid or immunosuppressive treatment.

Former reports have suggested that SLE is associated with dysfunction of the HPA axis and PRL secretion. Zietz et al found an altered function of the HPA axis in moderately active SLE; although baseline and stimulated serum androstenedione, cortisol, and dehydroepiandrosterone (DHEA) were lower in patients with SLE, plasma levels of ACTH were normal. This was not expected in patients receiving prednisolone. Furthermore, in relation to the level of IL6 or TNF, cortisol was clearly low compared with controls. In contrast, we did not find significant alterations of the HPA axis in patients with SLE who had not been treated. In the presence of an active autoimmune disease the failure to activate the HPA axis might be considered as an inadequate response to inflammatory stress. This is in line with data which show that levels of ACTH and cortisol are relatively low in relation to levels of IL6 and TNF in patients with untreated early rheumatoid arthritis (RA). Previous studies have also reported abnormal thyroid function tests in patients with SLE without known thyroid disease. SLE may be associated with autoimmune thyroiditis and a higher prevalence of hypothyroidism than the normal population, though reports are conflicting. Patients with SLE tested in our study had normal basal T₄ and TSH levels. However, compared with controls, stimulated TSH levels were significantly higher, suggesting latent hypothyroidism among patients. Unfortunately, we did not test autoantibodies against thyroid antigens.

GH has stimulatory effects on different immune functions. In juvenile RA abnormally low circadian secretion of GH has been measured. Furthermore, we have previously demonstrated a blunted GH response to GHRH in patients with RA. In contrast, no alteration of GH release could be detected here in patients with untreated SLE.

In vitro, PRL has been shown to augment lymphocyte proliferation. Moreover, raised serum PRL concentrations and PRL/cortisol ratio have been reported to be associated with autoimmunity in SLE. However, patients with prolactinomas have no signs of lymphocyte activation ex vivo. Here, among patients with SLE, basal and stimulated PRL levels were comparable with those of controls.

Mok et al concluded that ovarian failure with hypo-oestrogenaemia is protective against lupus flares. Furthermore, in lupus prone mice tamoxifen—an oestrogen antagonist—had beneficial effects, although a clinical trial showed no benefit of tamoxifen in women with SLE. Therefore it seems of interest that in our study no difference in basal sex hormone levels or in gonadotropin response to GnRH was found in premenopausal female patients compared with healthy controls. Findings obtained among male patients with SLE are of particular interest: two of the three men were clearly hypogonadal. Although the gonadotropin response to a supraphysiological GnRH dose was significantly enhanced, the lack of compensatory rise of basal LH concentrations suggests additional pituitary dysfunction. Together these data suggest profound primary hypogonadism but only mild pituitary dysfunction in association with SLE.

In another study a small cohort of four male patients with normal sexual activity and genital function showed decreased fertility based on sperm abnormalities, but these patients were receiving treatment with cytotoxic drugs. In contrast our patients had not received any previous immunosuppressive treatment. The finding of low basal and stimulated DHEA levels in female patients with RA as well as in patients with SLE, and the beneficial effect of DHEA treatment in patients with SLE, support the view that not only oestrogens but also androgens may participate in the pathogenesis of autoimmune diseases. Former studies have suggested that testosterone may directly suppress anti-DNA antibody production in peripheral blood mononuclear cells from patients with SLE by inhibiting B cell function. The report of significant clinical improvement of SLE symptoms during testosterone treatment provides further evidence for a role of androgens in SLE.

In summary, we found a differential state of pituitary end organ function in untreated SLE. The HPA axis appeared to be unaffected, which seems inadequate in view of continuing inflammation. In contrast, the pituitary-thyroid and pituitary-gonadal axes are clearly disturbed. The primary defect appears mainly in the peripheral endocrine organs, with an additional mild pituitary dysfunction. Thus, endocrine abnormalities are present among patients with SLE at (or before) the onset of disease.

**Authors’ affiliations**

M D Koller, J S Smolen, Clinic for Internal Medicine III, Department of Rheumatology, University of Vienna, Austria

E Tempel, M Riedl, M Clodi, A Lugner, Clinic for Internal Medicine III, Department of Endocrinology and Metabolism, University of Vienna, Austria

O Wagner, Institute of Clinical Chemistry and Laboratory Diagnostic, University of Vienna, Austria

Correspondence to: Dr M D Koller, Department of Internal Medicine III, Division of Rheumatology, General Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria; Marcus.Koeller@meduniwien.ac.at

Accepted 10 March 2004

Published Online First 13 April 2004

**REFERENCES**


Get published within days of acceptance with ARD

We are delighted to announce that the Annals of the Rheumatic Diseases launched a “publish ahead of print” programme in February 2004. Selected papers are fast tracked and published online months before they appear in the print journal.

Papers of major significance to the international rheumatology community are published within days of acceptance. The first published article is the raw accepted manuscript; edited and typeset versions are also published as soon as they are available.

In addition to being available on ARD Online, the publish ahead of print articles are searchable through PubMed/Medline—establishing primacy for your work. They are linked from the ARD Online home page.

ARD’s publish ahead of print programme is unique among the major rheumatology journals—to take advantage of this service submit your papers to Annals of the Rheumatic Diseases using our online submission and review system Bench>Press (http://submit-ard.bmjjournals.com). For further information contact ARD@bmjgroup.com.